Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

FDA Approves Infigratinib for FGFR2+ Cholangiocarcinoma

May 28th 2021

The FDA has approved infigratinib for the treatment of patients with previously treated locally advanced or metastatic cholangiocarcinoma harboring an FGFR2 fusion or rearrangement.

Uboha Underscores Latest Breakthroughs in Gastrointestinal Cancers

May 28th 2021

Nataliya V. Uboha, MD, PhD, zeros in on the developments with ADCs and monoclonal antibodies in gastric cancer and recent changes in pancreatic cancer as key takeaways from the event.

Research Collaboration Aims to Bring TLR9 Agonist SD-101 to Patients With Pancreatic and Liver Cancer

May 27th 2021

The University of Texas MD Anderson Cancer Center and the immuno-oncology company TriSalus™ Life Sciences announced a strategic research collaboration to evaluate SD-101 in pancreatic cancer and hepatocellular carcinoma.

Cemiplimab Granted Positive EU Opinion for Advanced NSCLC and Basal Cell Carcinoma

May 24th 2021

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of cemiplimab for use in 2 advanced cancers: non–small cell lung cancer and basal cell carcinoma.

Frontline Pembrolizumab/Chemo Recommended for EU Approval for Select Esophageal or HER2-Negative GEJ Adenocarcinoma

May 24th 2021

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of pembrolizumab plus platinum- and fluoropyrimidine-based chemotherapy for the frontline treatment of patients with locally advanced unresectable or metastatic esophageal carcinoma or HER2-negative gastroesophageal junction adenocarcinoma with PD-L1 positivity.

Maintenance Rucaparib Shows Efficacy in Advanced Pancreatic Cancer Harboring BRCA1, BRCA2, or PALB2

May 20th 2021

The PARP inhibitor rucaparib has proven to be a safe and effective maintenance option for patients with platinum-sensitive, advanced pancreatic cancer that harbors pathogenic variants such as BRCA1, BRCA2, or PALB2.

FDA Approves Adjuvant Nivolumab for Resected Esophageal or GEJ Cancer

May 20th 2021

The FDA has approved nivolumab for the adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease, in patients have received neoadjuvant chemoradiotherapy.

Dr. Sanjeevaiah on the Benefit of Immunotherapy Agents in Gastric Cancers

May 17th 2021

Aravind R. Sanjeevaiah, MD, discusses the benefit of immunotherapy agents in the treatment of patients with gastric cancers.

Zolbetuximab Plus EOX Improves Survival in Claudin 18.2+ Gastric/GEJ Cancers

May 17th 2021

The addition of the first-in-class chimeric monoclonal antibody zolbetuximab to frontline epirubicin, oxaliplatin, and capecitabine chemotherapy resulted in prolonged progression-free survival and overall survival compared with EOX alone in patients with advanced Claudin 18.2-positive gastric and gastroesophageal junction adenocarcinoma, according to the primary results of the phase 2 FAST trial.

Role of Adjuvant Chemoradiation Under Study in Gastric Cancer

May 16th 2021

Katelyn M. Atkins, MD, PhD, examines the evolving role of radiotherapy in the treatment of patients with gastric cancer, the subgroups who might derive the most benefit from this approach, and ongoing research efforts that are seeking to address remaining questions with this modality.

Gong Gives Perspective on Sequencing Challenges Faced in Advanced HCC

May 14th 2021

Jun Gong, MD, discusses the impact of the IMbrave150 trial on the advanced HCC treatment paradigm and challenges faced with sequencing.

Personalized, Adaptable Treatment Strategies May Improve Survival in Metastatic Gastroesophageal Cancer

May 12th 2021

Offering patients with metastatic gastroesophageal tumors a more personalized and adaptable treatment approach using monoclonal antibodies matched to genetic profiles in combination with chemotherapy may result in higher rates of survival compared with historic controls.

Rapid Readouts: A Global Study of Advanced Dosimetry in the Treatment of HCC With Y 90 Glass Microspheres

May 12th 2021

Riad Salem, MD, presents slides supporting global real-world data confirming a significant association between tumor-absorbed dose, objective response between tumor-absorbed dose and overall survival in patients with hepatocellular carcinoma (HCC) treated with yttrium-90 glass microspheres.

Dr. Janjigian on the FDA Approval of Nivolumab Plus Chemotherapy in Frontline Gastric Cancer

May 11th 2021

Yelena Y. Janjigian, MD, discusses the FDA approval of nivolumab plus chemotherapy in frontline gastric cancer.

Dr. Patel on Selecting Patients for Treatment With Atezolizumab/Bevacizumab in HCC

May 11th 2021

Monica A. Patel, MD, discusses factors that determine whether a patient with hepatocellular carcinoma is a good candidate to receive a combination of atezolizumab and bevacizumab.

FDA Grants Orphan Drug Designation to BOLD-100 for Gastric Cancer

May 11th 2021

The FDA has granted an orphan drug designation to the first-in-class ruthenium-based small molecule therapeutic BOLD-100 for the treatment of patients with gastric cancer.

Multidisciplinary Care Is Paramount as New Therapies Emerge in Metastatic Pancreatic Cancer

May 6th 2021

Although the standard-of-care treatment for patients with metastatic pancreatic cancer remains largely unchanged with multi-agent chemotherapy, the role for multidisciplinary care has expanded significantly in recent years.

The Future of Cancer Immunotherapy Lies in Combinational Approaches

May 6th 2021

Arsen Osipov, MD, discusses the potential for ongoing research with immunotherapeutic approaches in gastrointestinal malignancies, including CAR T-cell therapy, bispecific T-cell engagers, and vaccines.

Dr. Lee on Selecting a Treatment Approach for Neuroendocrine Tumors

May 6th 2021

Yoomi Lee, MD, discusses her process for selecting a treatment approach for patients with neuroendocrine tumors.

Dr. Uboha on Early Efficacy Data With Zanidatamab in HER2+ Upper GI Cancers

May 5th 2021

Nataliya V. Uboha, MD, PhD, discusses early efficacy data demonstrated with zanidatamab in HER2-expressing upper gastrointestinal cancers.